Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase I Dasatinib/Erlotinib in Recurrent NSCLC
This study is currently recruiting participants.
Study NCT00444015. Last updated on January 30, 2009.
Information provided by H. Lee Moffitt Cancer Center and Research Institute
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Non-Small-Cell Lung Carcinoma
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
More general conditions related to this trial
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Additional drug interventions recognized in this trial
Dasatinib
Erlotinib
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Sponsors listed in this trial
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb
Back to top of Main Content